The need for informed consent in off-label use in the EU
This article was originally published in SRA
C�ndido García Molyneux and Peter Bogaert explain the informed consent requirements for off-label use in the EU and discuss the potential for physician liability.
You may also be interested in...
Three years after rebranding from Concordia, Advanz Pharma is to be swallowed up by European-focused private equity Nordic Capital.
The goal is to create a program which mass sequences SARS-CoV-2 samples in order to detect new variants, with £30m injected into the UK's hub for genomic sequencing in Cambridge.
More than half a dozen generic rivaroxaban brands are now available in India, putting the heat on Bayer’s blockbuster anticoagulant Xarelto in the price-sensitive market. Many rival generics are priced over 50% lower than the innovator product.